{"id":1894,"date":"2022-03-25T10:19:25","date_gmt":"2022-03-25T10:19:25","guid":{"rendered":"https:\/\/www.ipsen.com\/spain\/?p=1894"},"modified":"2024-12-16T07:49:20","modified_gmt":"2024-12-16T05:49:20","slug":"ipsen-recibe-la-opinion-positiva-del-chmp-que-recomienda-cabozantinib-para-el-cancer-diferenciado-de-tiroides-refractario-al-yodo-radioactivo","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/spain\/press-releases\/ipsen-recibe-la-opinion-positiva-del-chmp-que-recomienda-cabozantinib-para-el-cancer-diferenciado-de-tiroides-refractario-al-yodo-radioactivo\/","title":{"rendered":"Ipsen recibe la opini\u00f3n positiva del CHMP que recomienda cabozantinib para el c\u00e1ncer diferenciado de tiroides refractario al yodo radioactivo"},"content":{"rendered":"\n